A patient with carcinoid syndrome has diarrhea and flushing partially controlled by octreotide. Which additional agent targeting serotonin specifically reduces the diarrhea refractory to octreotide?
- A Telotristat ethyl — an oral tryptophan hydroxylase inhibitor reducing peripheral serotonin synthesis in enterochromaffin cells ✓
- B Ondansetron — a 5-HT3 receptor antagonist blocking serotonin action at intestinal vagal afferents
- C Cyproheptadine — a combined H1/5-HT2 antagonist primarily for carcinoid flushing
- D Methysergide — a 5-HT2 receptor antagonist used as first-line for carcinoid diarrhea
Explanation
Telotristat ethyl is a peripherally restricted oral inhibitor of tryptophan hydroxylase-1 (TPH1), the rate-limiting enzyme for serotonin biosynthesis in peripheral enterochromaffin cells. Since carcinoid diarrhea is primarily driven by excessive serotonin from tumour enterochromaffin cells, blocking its synthesis upstream reduces stool frequency and urinary 5-HIAA levels, which are the validated clinical endpoints. Telotristat ethyl is approved specifically for carcinoid diarrhea inadequately controlled by somatostatin analogues (octreotide/lanreotide). It does not cross the blood-brain barrier significantly, so does not affect central serotonin. Ondansetron can symptomatically reduce diarrhea by 5-HT3 blockade but does not reduce serotonin synthesis or urinary 5-HIAA and is not the approved targeted agent.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.